[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599576":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":31,"responsibleParty":49,"collaborators":18,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":18,"enrollmentInfo":63,"targetDuration":18,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":78,"whyStopped":18,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"The First Affiliated Hospital of Anhui Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"rhBNP group","EXPERIMENTAL","The rhBNP group was given positive inotropic agents, increased mean arterial pressure, restricted intake, and increased the dosage of diuretics. At the same time, rhBNP will be administered a venous loading dose of 1.5\\~2μg\u002Fkg, refer to the instructions for a maintenance dose of 0.0075-0.01μg\u002Fkg\u002Fmin for continuous intravenous infusion for 72 hours.",[13],"Drug: rhBNP and standard basic treatment",{"label":15,"type":16,"description":17,"interventionNames":18},"control group","NO_INTERVENTION","The control group was given positive inotropic agents, increased mean arterial pressure, restricted intake, and increased the dosage of diuretics without rhBNP.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","rhBNP and standard basic treatment","After administering a bolus of rhBNP at 1.5-2 μg\u002Fkg intravenously, a maintenance dose of 0.0075-0.01 μg\u002Fkg\u002Fmin is continuously infused intravenously for 72 hours, with the dosage adjusted based on blood pressure and heart rate; the control group receives standard basic treatment.",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"qian gong","CONTACT","+86-18226616000","54xiaoqian@sina.com",[32],{"facility":33,"status":18,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"the First Affiliated Hospital of Anhui Medical University","Hefei","Anhui","230000","China","CN",{"type":40,"coordinates":41},"Point",[42,43],117.28083,31.86389,{"lat":43,"lon":42},[46],{"name":47,"role":28,"phone":48,"phoneExt":18,"email":30},"Gong qian, Doctor","+8618226616000",{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","GONG QIAN","Associate Chief Physician","100599576","evaluation-of-the-efficacy-of-rhbnp-in-patients-with-diuretic-resistance-after-cardiac-surgery-100599576",false,"NCT07086287","Evaluation of the Efficacy of rhBNP in Patients With Diuretic Resistance After Cardiac Surgery","Evaluation of the Efficacy of Recombinant Human Brain Natriuretic Peptide in Patients With Diuretic Resistance After Cardiac Surgery: a Prospective Single-center Single-blind Randomized Controlled Study","rhBNP","Inclusion Criteria:\n\n* (1) Adult patients after cardiac surgery (age ≥ 18 years) (2) Fluid overload (3) Diuretic resistance Definition: Daily intravenous use of furosemide at a dose ≥ 80mg or equivalent doses of other diuretics, yet still unable to achieve an adequate urine output of 0.5\\~1.0mL\u002Fkg\u002Fh. Conversion formula for different loop diuretics: Oral furosemide 80mg = Intravenous furosemide 40mg = Oral\u002FIntravenous torsemide 20mg = Oral\u002FIntravenous bumetanide 1mg (4) Willing to participate in the trial and sign the informed consent form.\n\nExclusion Criteria:\n\n* (1) Preoperative CKD patients undergo regular dialysis treatment; (2) Postoperative use of CRRT; (3) Drug allergies involved in this study; (4) Those with corrected systolic blood pressure still \\\u003C 90 mmHg after vasopressor use.","ALL","18 Years",{"count":64,"type":65},120,"ESTIMATED","INTERVENTIONAL",[68],"NA","evaluation of the efficacy of recombinant human brain natriuretic peptide in patients with diuretic resistance after cardiac surgery: a prospective single-center single-blind randomized controlled study",[71,72],"After Cardiac Surgery","Diuretic Resistance",[74,75,76,77],"recombinant human brain natriuretic peptide","diuretic resistance","after cardiac surgery","the incidence of renal replacement therapy","NOT_YET_RECRUITING","2025-07-18",{"date":81,"type":82},"2025-07-25","ACTUAL",{"date":84,"type":65},"2025-08-01",{"date":86,"type":65},"2028-06-30",{"name":5,"class":6},1]